CERTARA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17 USD | -0.35% |
|
-3.41% | -3.35% |
| May. 08 | Certara Q1 Adjusted Earnings Down, Revenue Increases | MT |
| May. 07 | Certara, Inc. Reiterates Earnings Guidance for the Year 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 391M | Sales 2025 * | 430M | Capitalization | 2.73B |
|---|---|---|---|---|---|
| Net income 2024 * | -6M | Net income 2025 * | 5M | EV / Sales 2024 * | 6.98 x |
| Net cash position 2024 * | 9.29M | Net cash position 2025 * | 96.48M | EV / Sales 2025 * | 6.13 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
222
x | Employees | 1,365 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.19% |
More Fundamentals
* Assessed data
More news
Latest transcript on Certara, Inc.
More recommendations
More press releases
| 1 day | -0.35% | ||
| 1 week | -3.41% | ||
| Current month | -0.64% | ||
| 1 month | -7.91% | ||
| 3 months | -1.33% | ||
| 6 months | +25.93% | ||
| Current year | -3.35% |
1 week
16.14
17.81
1 month
15.7818.38
Current year
15.3219.87
1 year
11.8122.65
3 years
10.6045.48
5 years
10.6045.48
10 years
10.6045.48
| Managers | Title | Age | Since |
|---|---|---|---|
William Feehery
CEO | Chief Executive Officer | 54 | 19-05-31 |
John Gallagher
DFI | Director of Finance/CFO | 51 | 23-03-31 |
Leif Pedersen
PSD | President | 60 | 20-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Matthew Walsh
BRD | Director/Board Member | 57 | 17-07-31 |
Cynthia Collins
BRD | Director/Board Member | 65 | 21-07-31 |
William Feehery
CEO | Chief Executive Officer | 54 | 19-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.91% | 4 M€ | -.--% | - | |
| 0.88% | 5 M€ | -1.80% | - | |
| 0.54% | 0 M€ | +4.88% | ||
| 0.12% | 0 M€ | +3.60% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 17 | -0.35% | 437,091 |
| 24-05-09 | 17.06 | +4.34% | 555,143 |
| 24-05-08 | 16.35 | -7.42% | 957,699 |
| 24-05-07 | 17.66 | +0.11% | 823,073 |
| 24-05-06 | 17.64 | +0.23% | 613,504 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotes
Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development in the global biopharmaceutical industry. It is focused on producing medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its customers include life sciences companies of all sizes along with contract research organizations, academic institutions, and global regulators. Its software and service are used by approximately 2,400 biopharmaceutical companies and academic institutions across 66 countries, including 38 of the top 40 biopharmaceutical companies. It has operations in the United States, Australia, Canada, China, France, Germany, India, Italy, Japan, Luxembourg, Netherlands, Philippines, Poland, Portugal, Spain, Switzerland, Egypt, and the United Kingdom.
Sector
Software
Calendar
2024-05-14
- BofA Securities Health Care Conference
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
17
USD
Average target price
19.72
USD
Spread / Average Target
+16.01%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.35% | 2.73B | |
| +10.29% | 3,082B | |
| +8.12% | 84.92B | |
| +5.55% | 78.23B | |
| -13.73% | 54.06B | |
| -24.43% | 46.79B | |
| +19.98% | 45.87B | |
| +21.26% | 42.65B | |
| +60.27% | 37.28B | |
| -9.36% | 24.89B |
- Stock Market
- Equities
- CERT Stock
